Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation-Reference-Cited by-同舟云学术

Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation

Published:2018-02 Issue: Volume:63 Page:48-60
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Ferris Robert L.,Lenz Heinz-Josef,Trotta Anna Maria,García-Foncillas Jesús,Schulten Jeltje,Audhuy François,Merlano Marco,Milano Gerard

Funder

Merck KGaA

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Reference123 articles.

1. Phase 1b trial of the toll-like receptor 8 agonist, motolimod (VTX-2337), combined with cetuximab in patients with recurrent or metastatic SCCHN;Chow;Clin Cancer Res,2017

2. Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients;Lo Nigro;World J Gastrointest Oncol,2016

3. Prospective evaluation of cetuximab-mediated antibody-dependent cell cytotoxicity in metastatic colorectal cancer patients predicts treatment efficacy;Trotta;Cancer Immunol Res,2016

4. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer;Mellor;J Hematol Oncol,2013

5. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma;Pahl;Clin Cancer Res,2012

Cited by 144 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances from targeted therapy for non‐metastatic HER2‐positive inflammatory breast cancer;Journal of Surgical Oncology;2024-08-05

2. Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment;Cancer Letters;2024-08

3. A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody;ESMO Open;2024-06

4. PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review;International Journal of Colorectal Disease;2024-05-29

5. Efficacy of nimotuzumab in combination with immunotherapy for a young recurrent cervical cancer patient: a case report and literature review;Anti-Cancer Drugs;2024-05-20